JPMorgan Maintains Overweight Rating on Bruker Corporation

On June 8, JPMorgan analyst Casey Woodring raised Bruker Corporation's (NASDAQ:BRKR) price target to $65 from $45 and maintained an 'Overweight' rating. The firm cited advancements in microbiology diagnostics, including FDA-approved updates for the MALDI Biotyper CA System.

By Fatima Gulzar Sat, June 27, 2026 at 6:31 PM GMT+3 1 min read · Yahoo Finance · June 27, 2026, 15:31 UTC

JPMorgan Maintains Overweight Rating on Bruker Corporation

Tickers: $BRKR $BRKRP $JPM

Topics: analyst update biotechnology diagnostics stock rating

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy TechCrunch · November 12, 2026, 18:39 UTC
Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy Seeking Alpha · November 12, 2026, 18:35 UTC
EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC